Risk of Intraepithelial Neoplasia Grade 3 or Worse (CIN3+) among Women Examined by a 5-Type HPV mRNA Test during 2003 and 2004, Followed through 2015

The study's purpose was to evaluate the performance of a five-type HPV mRNA test to predict cervical intraepithelial neoplasia grade 3 or worse (CIN3+) during up to 12 years of follow-up. Overall, 19,153 women were recruited by gynecologists and general practitioners in different parts of Norwa...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-06, Vol.15 (12), p.3106
Main Authors: Rad, Amir, Sørbye, Sveinung Wergeland, Tiwari, Sweta, Løchen, Maja-Lisa, Skjeldestad, Finn Egil
Format: Article
Language:English
Subjects:
Age groups
Biopsy
Cancer
Cancer screening
Cellular biology
Cervical cancer
Cytology
Diagnosis
Genetic testing
Histology
Human papillomavirus
Laboratories
Longitudinal studies
Medical screening
Medical tests
Messenger RNA
mRNA
Papillomavirus infections
Population studies
Prevention
Statistical analysis
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study's purpose was to evaluate the performance of a five-type HPV mRNA test to predict cervical intraepithelial neoplasia grade 3 or worse (CIN3+) during up to 12 years of follow-up. Overall, 19,153 women were recruited by gynecologists and general practitioners in different parts of Norway between 2003 and 2004. The study population comprised 9582 women of these women, aged 25-69 years with normal cytology and a valid five-type HPV mRNA test at baseline. Follow-up for CIN3+ through 2015 was conducted in the Norwegian Cervical Cancer Screening Programme. The cumulative incidence of CIN3+ by baseline status for HPV mRNA-positive and mRNA-negative women were 20.8% and 1.1%, respectively ( < 0.001). Age did not affect the long-term ability of the HPV mRNA test to predict CIN3+ during follow-up. The low long-term risk of CIN3+ among HPV mRNA-negative women and the high long-term risk among HPV mRNA-positive women strengthen the evidence that the five-type HPV mRNA test is an appropriate screening test for women of all ages. Our findings suggest that women with a negative result may extend the screening interval up to 10 years.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15123106